The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM).
 
Ryan J. Sullivan
Consulting or Advisory Role - alkermes; Asana Biosciences; AstraZeneca; Bristol-Myers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Viralytics (Inst)
 
Mohammed M. Milhem
Consulting or Advisory Role - Exicure
Research Funding - Amgen (Inst); E.R. Squibb Sons, LLC (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst)
 
Lev V. Demidov
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
 
Karl D. Lewis
Honoraria - Array BioPharma; Iovance Biotherapeutics
Consulting or Advisory Role - Array BioPharma; Iovance Biotherapeutics; Merck; nektar; Regeneron; Roche; Sanofi
Research Funding - alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); Merck (Inst); Nektar (Inst); Neon Therapeutics (Inst); OncoSec (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - alkermes; Merck; Neon Therapeutics; Regeneron; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Regeneron; Roche/Genentech
 
Max Schlaak
Honoraria - Bristol-Myers Squibb; Genzyme; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Immunocore; Recordati; Sanofi/Aventis
 
Sophie Piperno-Neumann
Consulting or Advisory Role - Immunocore
Research Funding - MSD (Inst); Novartis (Inst)
 
Shaad Essa Abdullah
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
Patents, Royalties, Other Intellectual Property - AU2019270277A1 - Treatment of Cancer; WO2020225552A1 - Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
 
Claire Watkins
Consulting or Advisory Role - Actinium Pharmaceuticals; Amylyx; Ascelia; Astellas Pharma; AstraZeneca; Celgene/Bristol-Myers Squibb; Evgen; F2G; Humanigen; Immunocore; Kite/Gilead; Nobelpharma; Roche
 
Howard Goodall
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
 
John M. Kirkwood
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Amgen; Ankyra Therapeutics; AXIO Research; Becker Pharmaceutical Consulting; Checkmate Pharmaceuticals; DermTech; Fenix Group International; Harbour BioMed; Immunocore; Intellisphere, LLC; Iovance Biotherapeutics; IQVIA; Istari Oncology; Merck; Natera; Novartis; Oncocyte; OncoSec; Pfizer; Replimune; Scopus BioPharma; SR One Capital Management; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Harbour BioMed (Inst); Immunocore (Inst); Immvira (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Novartis (Inst); Schering-Plough (Inst); Takeda (Inst); Verastem (Inst)